US 12,357,621 B2
BET inhibitors as a treatment for myelofibrosis
Ida Aronchik, Burlingame, CA (US); Roxxana Valeria Beltran Valencia, South San Francisco, CA (US); Maria Soraya Carrancio Anton, San Diego, CA (US); Henry H. Chang, San Francisco, CA (US); Shodeinde Coker, Princeton, NJ (US); Sharmila Das, North Brunswick, NJ (US); Ellen Hope Filvaroff, San Francisco, CA (US); Carla Guarinos Marhuenda, Alicante (ES); Bishoy Hanna, Woodbridge, NJ (US); Yu Liu, Brookline, MA (US); Zariana Nikolova, Basel Land (CH); and Oriana Esposito, Ticino (CH)
Filed by Impact Biomedicines, Inc., Summit, NJ (US)
Filed on Feb. 25, 2022, as Appl. No. 17/680,569.
Claims priority of provisional application 63/297,098, filed on Jan. 6, 2022.
Claims priority of provisional application 63/232,866, filed on Aug. 13, 2021.
Claims priority of application No. 21382163 (EP), filed on Feb. 25, 2021.
Prior Publication US 2022/0265617 A1, Aug. 25, 2022
Int. Cl. A61K 31/437 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/437 (2013.01) [A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 13 Claims
 
1. A method of treating myelofibrosis in a subject in need thereof, the method comprising orally administering to the subject:
a compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; and
a compound of formula (II):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt and/or solvate thereof;
wherein the compound of formula (I), or the pharmaceutically acceptable salt thereof, is administered at a daily dose of 0.25 mg, 0.5 mg, 0.75 mg, or 1.0 ma on a five days on, two days off schedule for three weeks, and wherein the compound of formula (II), or the pharmaceutically acceptable salt and/or solvate thereof, is administered at a daily dose of about 400 mg.